FDA Approves Sovaldi (Sofosbuvir) for Chronic Hepatitis C
Drug Is Third With Breakthrough Therapy Designation to Receive FDA Approval
December 6, 2013
The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.
"Today's approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.
Sovaldi is the second drug approved by the FDA in the past two weeks to treat chronic HCV infection. On November 22, theView Full Article
Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)